Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients

Survivin is an inhibitor of apoptosis. Aberrant survivin expression occurs in malignant tumors and has often been linked to unfavorable patient outcome. Here we analyzed 12 432 prostate cancers by immunohistochemistry. Survivin immunostaining was regularly expressed at high levels in normal prostate...

Descripción completa

Detalles Bibliográficos
Autores principales: Büscheck, Franziska, Sulimankhil, Mariam, Melling, Nathaniel, Höflmayer, Doris, Hube‐Magg, Claudia, Simon, Ronald, Göbel, Cosima, Hinsch, Andrea, Weidemann, Sören, Izbicki, Jacob R., Jacobsen, Frank, Mandelkow, Tim, Blessin, Niclas C., Möller‐Koop, Christina, Lutz, Florian, Viehweger, Florian, Möller, Katharina, Sauter, Guido, Lennartz, Maximillian, Burandt, Eike, Lebok, Patrick, Minner, Sarah, Bonk, Sarah, Huland, Hartwig, Graefen, Markus, Schlomm, Thorsten, Fraune, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013067/
https://www.ncbi.nlm.nih.gov/pubmed/31893572
http://dx.doi.org/10.1002/cam4.2773

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013067/
https://www.ncbi.nlm.nih.gov/pubmed/31893572
http://dx.doi.org/10.1002/cam4.2773

Ejemplares similares